

## *Atherosclerosis: Achieving Optimal Outcomes in Statin Therapy*

This supplement to *The American Journal of Managed Care* is based on 2 symposia, one that occurred during the European Society of Cardiology meeting in The Netherlands and the other that took place during the American Heart Association meeting in New Orleans.

This supplement has been peer reviewed by an expert in the field.

---

### *Faculty*

**Christie M. Ballantyne, MD**

Associate Chief,  
Clinical Director, Section  
of Atherosclerosis  
Department of Medicine  
Director, Atherosclerosis and  
Lipid Laboratory  
Baylor College of Medicine  
Houston, Texas

**Philip J. Barter, MD, PhD, FRACP**

Professor of Cardiology  
Royal Adelaide Hospital  
Cardiology Department  
Adelaide, Australia

**W. Virgil Brown, MD**

Charles Howard Candler Professor  
of Medicine  
Director, Division of  
Arteriosclerosis and  
Lipid Metabolism  
Emory University School  
of Medicine  
Atlanta, Georgia  
Chief, Medicine and Primary Care  
Service  
Atlanta VA Medical Center  
Decatur, Georgia

**Allan Gaw, MD, PhD**

Director of Clinical Trials Unit  
Glasgow Royal Infirmary  
Glasgow, United Kingdom

**Anders G. Olsson, MD, PhD**

Head, Clinical Research Centre  
Professor of Internal Medicine  
University Hospital in Linköping  
Linköping, Sweden

**Terje Pedersen, MD, PhD**

Professor of Clinical Cardiology  
Cardiology Department  
Aker Hospital  
University of Oslo  
Oslo, Norway

**Frank M. Sacks, MD**

Professor  
Harvard Medical School  
Department of Nutrition  
Harvard School of Public Health  
Boston, Massachusetts

**Ernst Schaefer, MD**

Professor of Medicine  
New England Medical Center  
Boston, Massachusetts

**Robert Vogel, MD**

Herbert Berger Professor  
of Medicine  
Head/Division of Cardiology  
University of Maryland Hospital  
Baltimore, Maryland

**David D. Waters, MD**

Professor of Medicine  
Chief, Division of Cardiology  
University of California,  
San Francisco School of Medicine  
San Francisco, California

---

## DISCLOSURE STATEMENT

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

These participants have declared the following affiliations with corporate organizations.

■ **Christie M. Ballantyne, MD**

*Member of the Speakers' Bureau  
For/Research Support  
From/Consultant To:*  
AstraZeneca  
Pfizer  
Merck  
Novartis  
Reliant

■ **Philip J. Barter, MD, PhD**

*Lecture Support From/Member of  
an Advisory Board For:*  
Pfizer  
AstraZeneca  
Merck, Sharp and Dohme  
*Research Support From:*  
Pfizer  
Fournier  
Merck, Sharp and Dohme

■ **W. Virgil Brown, MD**

*Member of the Speakers' Bureau  
For/Research Support  
From/Consultant To:*  
Bristol-Myers Squibb  
Parke-Davis  
Warner-Lambert  
Pfizer  
Merck  
Novartis  
Bayer  
AstraZeneca  
Kos Pharmaceuticals  
Abbott Laboratories  
SmithKline Beecham  
Pharmaceuticals  
Sankyo Pharmaceuticals  
Merck/Schering-Plough

■ **Allan Gaw, MD, PhD**

*Research Support For/  
Consultant To:*  
Bristol-Myers Squibb  
AstraZeneca  
Merck, Sharp and Dohme

■ **Anders G. Olsson, MD, PhD**

*Advisor To:*  
Bayer  
Bristol-Myers Squibb  
Merck  
Novartis  
*Advisor To/Research Support  
From:*  
Pfizer  
AstraZeneca

■ **Terje Pedersen, MD, PhD**

*Lecture, Research Support  
From/Advisor To:*  
Merck  
Pfizer  
AstraZeneca  
Bayer/Fournier  
Sankyo Pharmaceuticals  
Schering-Plough

■ **Frank M. Sacks, MD**

*Lecture Support From:*  
Abbott  
AstraZeneca  
Bristol-Myers Squibb  
Fournier  
Kos Pharmaceuticals  
*Advisor To:*  
AstraZeneca  
Bristol-Myers Squibb  
Fournier  
Bayer  
*Research Support From:*  
Bristol-Myers Squibb

■ **Ernst Schaefer, MD**

*Grant Support From:*  
National Institutes of  
Health  
Pfizer  
Kos Pharmaceuticals  
United States Department  
of Agriculture

■ **Robert Vogel, MD**

*Research Support From:*  
Pfizer  
Schering-Plough

■ **David D. Waters, MD**

*Investigator-Initiated Research  
Findings/Lecture Support  
From:*  
Merck  
AstraZeneca  
Pfizer

---

Signed disclosures are on file at the offices of *The American Journal of Managed Care*, Jamesburg, New Jersey.

---

*Atherosclerosis: Achieving Optimal Outcomes  
in Statin Therapy*

This program is supported by an unrestricted educational grant from **AstraZeneca LP**.



The content of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.